SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as community members debate whether a post-earnings dip signals an overvalued stock or a buying opportunity. Some traders point to Michael Burry's reported short position as a bearish signal, while others highlight the company's growth and potential in the AI sector. Discussions also include CEO Alex Karp's commentary and its potential impact on the stock.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid a broader crypto selloff, with the community debating potential bottom prices and the influence of external factors like government shutdowns and the TradFi market. Traders are closely watching technical indicators, while some express frustration with price predictions from crypto analysts. Liquidations and market manipulation remain key concerns.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts on AI and data centers, sparking concerns about near-term profitability despite strong revenue growth. Community sentiment is largely bearish, with traders discussing potential support levels and questioning the company's valuation relative to its peers. Some traders are looking for a potential bounce, while others are bracing for further declines.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending as the community discusses a potential breakout and run, with some pointing to its strong technology and on-chain development. Despite some skepticism and concerns about its past performance, bullish investors highlight its potential for high APR yields and long-term growth. Some community members believe it's primed for a significant pump, while others remain cautious.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as the community discusses its recent price movements and potential for growth, with some speculating about a possible rally. Talk centers around strategic partnerships and accumulation, while others express frustration with volatility and missed opportunities. Recent news of institutional stablecoins being built on AVAX may be contributing to the increased interest.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending following a strong earnings report driven by growth in cloud services and AI, with some analysts projecting significant price increases. The community is discussing the potential impact of Google's AI investments and comparing its performance to competitors like Meta and Microsoft. Additionally, Waymo's expansion into new cities and a potential partnership with Apple's Siri are sparking interest.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to a significant after-hours drop following its Q3 earnings release and DMD trial results, sparking concerns about the future of its PMO therapies; however, the ELEVIDYS sales beat offers some optimism. The community is debating the severity of the trial's impact, potential FDA actions, and whether this presents a buying opportunity or signals deeper issues, with some speculating about a potential buyout. Some bullish investors are highlighting the potential for mass manipulation.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid discussions around its Q3 earnings, which showed significant revenue growth, and its position as a leading U.S. uranium producer. The community is weighing the implications of a potential pullback in rare earth tariffs and export controls, while also considering Energy Fuels' long-term prospects in the nuclear energy and rare earth elements sectors, particularly given its zero debt balance sheet. Some traders are closely monitoring technical indicators and options activity to gauge potential entry points and price movements.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community discusses the potential impact of a competitor's (Sarepta) recent clinical trial setback on CAPR's DMD treatment, Deramiocel.  Many see this as an opportunity for Capricor, with some investors suggesting it is now the 'last DMD company alive'. Upcoming P3 data is a key focus, and speculation surrounds the timing of its release.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

XLM is trending as the community debates recent price action and potential future movement, with some expressing frustration over perceived underperformance. Discussions include potential correlation with broader market trends and speculation around upcoming news and developments within the Stellar ecosystem. A mix of bullish and bearish sentiment is present, with some traders looking at the dips as buying opportunities for long-term holds.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETF Areas to Buy on Fed Cuts and Trade Truce Optimism

Fed turns dovish and trade tensions ease. Amid this scenario, tech & growth ETFs could soar along with some other areas. Watch SMH, QQQ, SPYG & IWO as markets may be up for a renewed rally.

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

Equity

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

Tvardi Therapeutics (TVRD) on Monday said that its TTI-101, being evaluated in idiopathic pulmonary fibrosis (IPF), showed no benefit over placebo in a mid-stage trial.The trial was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function in patients with IPF. Idiopathic Pulmonary Fibrosis is a progressive lung disease where lung tissue thickens and scars, making it difficult to breathe. However, the study did not meet its goals, and no statistically significant differences between placebo and treatment arms were observed after a preliminary review of exploratory efficacy, it said.Shares of the company plummeted 87% in Monday’s pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVRD">TVRD stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.Tvardi said that preliminary data showed that patients’ baseline characteristics were mostly similar across treatment arms, including those who received the two doses of TTI-101 or those who received a placebo in the trial. Furthermore, lower discontinuation rates were observed in the placebo group compared to the therapy-treated arms, it added.The company also noted that patients who demonstrated changes in the lung’s Forced Vital Capacity (FVC) were 41% for the placebo, and 39% and 44% for the 400mg and 800mg TTI-101-treated arms, respectively.“In the aggregate, we did not observe a benefit of TTI-101 treatment in this IPF study. The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time,” CEO Imran Alibhai said.The CEO added that the company is now conducting additional analyses to understand the trial findings further. He also noted that the company is on track to report preliminary data from the mid-stage trial of TTI-101 in hepatocellular carcinoma.TVRD stock has risen about 127% this year and more than quadrupled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-commences-production-ramp-up-at-shanghai-gigafactory/ch6SiqpR3kW">Tesla Reportedly Commences Production Ramp-Up At Its Shanghai Gigafactory</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?

The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review of exploratory efficacy. 

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

SoundHound AI, Inc.(SOUN) on Wednesday said it has teamed up with Apivia Courtage, part of the AEMA Group, to bring advanced AI agents into the insurer’s contact centers using SoundHound’s Amelia 7 platform.Under this collaboration, Apivia Courtage will roll out Amelia 7, an AI agent system designed to act autonomously, as a key component of its digital overhaul strategy, building on the success with SoundHound’s platform, which resulted in a 20% productivity boost.<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI stock</a> traded over 8% higher on Wednesday afternoon. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘normal message volume levels.<figure class="image"><img style="aspect-ratio:925/100;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_08_130638_png_e64e4f8927.webp" alt="SOUN’s Sentiment Meter and Message Volume as of 12:45 p.m. ET on Oct. 8, 2025 | Source: Stocktwits" width="925" height="100"><figcaption>SOUN’s Sentiment Meter and Message Volume as of 12:45 p.m. ET on Oct. 8, 2025 | Source: Stocktwits</figcaption></figure>The stock saw a 161% increase in user message count in the last month, as per platform data. A Stocktwits user expressed confidence in the partnership, stating that the company is a “huge player” in France.<stembedurl>https://stocktwits.com/Ibiolegends/message/631509252</stembedurl>Amelia’s architecture blends large language models’ reasoning and planning with structured rule‑driven workflows. It also supports escalation to humans when needed. The AI agents operate across multiple channels, including voice, chat, and text.With Amelia 7’s “agentic” capabilities, Apivia aims to let customers self‑serve on more types of inquiries without human intervention. The AI agents will interpret multiple intents in a single interaction, carry out tasks like identity verification via one-time passwords, answer policy questions, update contact details, compute the financial impact of contract changes, and initiate quotes or book meetings with advisors.Since 2023, the two companies have worked together to integrate AI agents alongside human staff at Apivia’s call centers. SoundHound AI stock has gained over 317% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-hits-all-time-high-after-nvidia-ceo-jensen-huang-calls-offering-10-percent-stake-to-open-ai-clever/ch6EpkDR30b">AMD Hits All-Time High After Nvidia CEO Jensen Huang Calls Offering 10% Stake To OpenAI ‘Clever’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Amelia logo is being displayed on a mobile phone screen in front of a monitor displaying SoundHoundAI logo in Ankara, Turkiye on August 27, 2024. 

SoundHound, Apivia Deploy Agentic AI For Insurance Contact Centers: Retail Sentiment Jumps

Under the partnership, Apivia Courtage will roll out Amelia 7, an AI agent system designed to act autonomously, building on earlier success where SoundHound’s platform boosted productivity by 20%.

Small-Cap Wins in Q3: Top-Performing ETFs in Focus 

Small caps staged a comeback in Q3, with ETFs like FESM, RZV, FYX, VTWV, JSML, IWO topping gains. While there are certain tariff risks, the Fed's rate cut potential is a plus. 

SoundHound AI Inc. (SOUN) stock was in the spotlight on Monday morning after the shares received an upgrade from Ladenburg Thalmann, which raised its rating to ‘Buy’ from ‘Neutral’ and raised the price target to $16 from $9.&nbsp;The brokerage cited strong second-quarter (Q2) results and successful execution on large enterprise deals as key reasons for its upgrade, as per TheFly.&nbsp;<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI stock</a> shot up over 13% on Monday morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.<figure class="image"><img style="aspect-ratio:955/110;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_095242_png_df04a03eb4.webp" alt="SOUN’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="955" height="110"><figcaption>SOUN’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 176% increase in user message count over 24 hours, as of Monday morning. A Stocktwits user said the business has ‘great demand’.<stembedurl>https://stocktwits.com/Tekoa/message/624580522</stembedurl>Another user commended the Q2 earnings print.<stembedurl>https://stocktwits.com/paaps/message/624567480</stembedurl>Ladenburg sees sales growth momentum as justifying its increased spending levels. The brokerage remains optimistic about the opportunity in voice-based artificial intelligence, identifying it as one of the most promising early-use cases in the AI space.&nbsp;The firm believes SoundHound’s products cater to businesses that want to integrate AI-driven voice features into their operations.The company’s Q2 revenue jumped 217% year-on-year (YoY) to $42.7 million, beating the analysts’ consensus estimate of $32.88 million, as per Fiscal AI data. The adjusted loss per share of $0.03 came in wider than the consensus estimate of a loss of $0.01.The company raised its FY2025 revenue guidance to a range of $160 million and $178 million. On August 7, SoundHound launched Vision AI, a visual recognition engine built directly into its voice-centric platform.SoundHound AI stock has lost over 24% year-to-date and has gained over 190% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/black-monday-for-monday-dot-com-stock/chruzItRdeT">Black Monday For Monday.Com Stock? Here’s What Co-CEO Roy Mann Said About Google Algorithm Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Binary code displayed on a laptop screen displayed on a laptop screen and SoundHound AI logo displayed on a phone screen are seen in this illustration photo taken in Krakow, Poland on August 8, 2025. 

SoundHound Stock Surged 13% Today – And Ladenburg Thalmann Has A New Price Target 

The firm cited strong second-quarter results and successful execution on large enterprise deals as key reasons for the upgrade.

SoundHound stock was the top-trending equity ticker on Stocktwits late Thursday as retail investors reacted to the conversational artificial intelligence (AI) company announcing a beat-and-raise quarter.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SOUN">SoundHound stock</a> turned to ‘extremely bullish’ (88/100) by late Thursday from ‘neutral’ a day ago. The message volume also picked up pace to ‘extremely high’ levels.&nbsp;The 24-hour message volume change leading up to late Thursday was about 500%.<figure class="image"><img style="aspect-ratio:618/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_10_15_05_PM_png_18725d4ece.webp" alt="Screenshot 2025-08-07 at 10.15.05 PM.png" width="618" height="54"><figcaption>SOUN sentiment and message volume as of 10:15 p.m. ET, Aug. 7 | source: Stocktwits</figcaption></figure>Santa Clara, California-based SoundHound reported a loss of $0.03 per share on an adjusted basis for the second quarter of the fiscal year 2025, narrower than the year-ago loss of $0.04 and the Factset-compiled consensus of $0.05 per share.Revenue climbed 217% year-over-year to $42.68 million, sharply higher than the $32.9-million consensus estimate.Co-founder and CEO Keyvan Mohajer said, “In SoundHound’s strongest ever quarter, many of our previous strategic moves delivered high-impact results with growth across every business unit.”“We realized significant new wins as well as cross-sell deals, demonstrating the incredible opportunity we predicted with our 2024 acquisitions.”SoundHound ended the quarter with cash and cash equivalents of $230 million as of June 30 and boasted of no debt on its balance sheet.The company raised its full-year revenue outlook to a range of $160 million to $178 million from a range of $157 million to $177 million.Underlining the massive potential for conversational AI,&nbsp;Mark Zuckerberg’s Meta&nbsp;Platforms Inc.&nbsp;made its second voice AI startup acquisition, WaveForms, according to a report by The Information, just a month after purchasing PlayAI.Commenting on Stocktwits, a bullish watcher&nbsp;noted that a majority of the volume in SoundHound stock over the past week was from dark pool or off-exchange transactions. They also noted that the short interest was high,&nbsp;which they considered a positive for the underlying stock.<stembedurl>https://stocktwits.com/notihimself/message/624253898</stembedurl>The short interest in the stock is currently at 30.32%, according to Koyfing, and it has remained above this level since late May.Another user&nbsp;considered the stock price to be too low, noting that it was trading at double the current levels at the start of the year and that the earnings report indicated the company was performing well.<stembedurl>https://stocktwits.com/DakotaDan1/message/624252035</stembedurl>SoundHound stock has grossly underperformed the broader market, having lost 46% this year. In overnight trading, the stock was up over 14%, and if&nbsp;gains carry over into Friday’s session, it&nbsp;would mark its best session since late May, according to Koyfin data.The Koyfin-compiled average analysts’ price target for the stock is $11.81, implying upside potential of over 10%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-stock-marks-worst-day-in-25-years-as-weight-loss-pill-data-disappoints-analysts-divided-but-retail-bets-on-rebound/chrVvOxRd3V">Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound</a>

SoundHound Retail Traders Brace For More Stock Gains After Voice AI Player Reports ‘Strongest-Ever Quarter’

The company’s Q2 revenue soared 217% year-over-year to $42.68 million, sharply higher than the $32.9-million consensus estimate.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 Growth ETF

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

IWO
iShares Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWO News

IWOiShares Russell 2000 Growth ETF